AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up

Sept 28 (Reuters) – Summit Therapeutics said on Monday that British drugmaker AstraZeneca would invest $2 billion in the company and collaborate on a series of studies testing their cancer treatments

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)